17-Hydroxyprogesterone, Urine
17-hydroxyprogesterone (17-OHP) is produced by the adrenal cortex, gonads, and placenta. It is the metabolic product of progesterone and is a precursor to cortisol. 17-OHP is markedly elevated in congenital adrenal hyperplasia (CAH). Measurement of 17-OHP is therefore valuable in the initial diagnosis of CAH.
CAH is a group of autosomal recessive inherited disorders caused by specific gene mutations and associated with cortisol-related enzyme deficiencies. More than 95% of CAH cases are caused by a mutation in the CYP21A2 gene that metabolizes and regulates 17-OHP. This leads to a 21-hydroxylase deficiency and accumulation of 17-OHP in the blood. Up to 75% of newborns affected by CAH will also produce less aldosterone, a hormone that regulates salt retention. The loss of too much fluid and salt in the urine can lead to life-threatening adrenal crisis, or "salt-wasting" crisis.
In addition, in the most common form of CAH, deficiency of the 21-hydroxylase enzyme blocks normal synthesis of cortisol, leading to a compensatory increase of ACTH secretion. This results in adrenal hyperplasia with increased levels of 17a-hydroxyprogesterone, DHEA, and other adrenal steroids. 17-OHP testing is mainly used as part of newborn screening for the detection of CAH. CAH is a common cause of female hermaphroditism, an autosomal recessive disease.
17-OHP serum levels exhibit a diurnal pattern similar to cortisol, and increase during the luteal phase of the menstrual cycle and during pregnancy. Levels of pregnanetriol, cortisol, and ACTH can also be helpful in the diagnosis of CAH.
- In the diagnosis of congenital adrenal hyperplasia
- Newborn screening for congenital adrenal hyperplasia
- To evaluate hirsutism, infertility, and/or hermaphroditism in female patients with possible 21-hydroxylase deficiency
- To assess certain adrenal and ovarian tumors which may have endocrine activity
Increased in:
- Congenital adrenal hyperplasia
- Hirsutism
- Hermaphroditism
Decreased in:
- Infertility
Children (puberty): 0-100 ng/dL (SI: 0-3.0 mmol/L)
Follicular: 22-85 ng/dL (SI: 0.7-2.5 mmol/L)
Luteal: 100-300 ng/dL (SI: 3.0-9.0 mmol/L)
Postmenopausal: 0-50 ng/dL (SI: 0-1.5 mmol/L)
Urine collected in a sterile container.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Horm Res. 1988;30(6):235-40. [PMID: 3250925]
- J Clin Endocrinol Metab. 2005 Jul;90(7):3904-7. [PMID: 15797960]
- J Pediatr Adolesc Gynecol. 2011 Jun;24(3):116-26. [PMID: 21601808]
- Endocrinol Metab Clin North Am. 2009 Dec;38(4):699-718. [PMID: 19944288]
- Clin Chem Lab Med. 2010 Aug;48(8):1057-62. [PMID: 20482300]
- Nat Clin Pract Endocrinol Metab. 2006 Feb;2(2):74-5. [PMID: 16932259]
- J Clin Endocrinol Metab. 2004 Aug;89(8):3685-6. [PMID: 15292288]
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757.